Medical Decision Modeling Inc. (MDM) is a health economic consulting and software development firm with a 24-year history of successfully serving a diverse array of global clients.
At its core, MDM is committed to successfully developing, analyzing, and communicating scientifically-defensible health and economic value messages for our client’s external and internal stakeholders. MDM provides a wide range of global health outcomes research services with a focus on pharmacoeconomic modeling, database and statistical analyses, sophisticated evidence synthesis methods, reimbursement dossiers, and systematic literature reviews.
To date, MDM has conducted over a thousand commercial modeling and evidenced-based projects with leading pharmaceutical, biotechnology, and medical device companies, as well as university medical research centers. Each of these involved the integration, analysis, and presentation of clinical evidence to research and quantitatively analyze the benefits, risks, and costs of pharmaceuticals, biotechnologies, or medical devices. MDM has been involved in early analysis of assets (pre-phase I) through assisting in go-to-market HTA submissions and contributing in the achievement of new indications for previously approved assets.
Through 2018, MDM’s work has been used for analyses in 24 countries (Australia, Brazil, Canada [and Quebec, independently], China, Colombia, The Czech Republic, France, Germany, England, Hong Kong, Hungary, Italy, Japan, Mexico, The Netherlands, Poland, Russia, Scotland, South Korea, Spain, Sweden, Taiwan, Turkey, and the US).
MDM incorporated in 1997 (its predecessor, Smolen & Associates, was founded in 1994). The senior research team at MDM averages over 33 years of modeling and health outcomes research experience, and over 14 years of tenure at MDM.